BioSpace News Archive

Eagle Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH, a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the commercial availability of additional vial sizes of BIVIGAM and NABI-HB, which are currently in stock and commercially available to U.S healthcare providers and patients.

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that recruitment is open to patients in Canada for the Phase 3 pivotal clinical program of OPT-302 for the treatment of wet age-related macular degeneration.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 20,000 shares of KalVista common stock on August 3, 2021 as inducements material to each employee entering into employment with KalVista.

Genesis Innovation Group’s cultivate(MD) Capital Fund II LP, a fund focused on investments into early-stage healthcare companies with innovative technologies, announced today that one of their portfolio companies, SpinTech, has received FDA 510(k) clearance for their STAGETM magnetic resonance imaging software.

Cipher Pharmaceuticals Inc. today announced it will release its Q2 2021 financial results on Thursday, August 12 , 2021. The company will hold a conference call on Friday, August 13, 2021 to discuss the results.

Nuvo Pharmaceuticals Inc. dba Miravo to Host Conference Call/Audio Webcast August 9th at 11:00 a.m. ET

Epizyme, Inc., a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies announced its Chief Executive Officer succession plan, with industry veteran Grant Bogle succeeding Robert Bazemore, as President and CEO.

Avinger, Inc. today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.

Dante Labs announced today the appointment of Mark Morgan as a board member.